Below are the most recent publications written about "Cardiomyopathy, Hypertrophic" by people in Profiles.
-
Weiner SD, Liang LW, Masri A, Abraham TP, Barriales-Villa R, Cooper RM, Elliott PM, de Feria A, Maron MS, Oreziak A, Saberi S, Solomon SD, Spertus JA, Tower-Rader A, Butzner M, Godown J, Heitner SB, Jacoby DL, Kupfer S, Liu X, Malik FI, Melloni C, Simkins TJ, Wei J, Nassif ME, Owens AT. Long-term impact of aficamten on patient-reported outcome measures in obstructive hypertrophic cardiomyopathy: results from FOREST-HCM. Eur J Heart Fail. 2026 Oct 28; 28(4):819-830.
-
Hegde SM, Wang X, Bhatia A, Peña-Peña ML, Sherrid MV, Figueiredo EL, Arad M, Barriales-Villa R, Choudhury L, Claggett BL, Coats CJ, de Barros Correia E, Costabel JP, Elliott PM, Silva Enciso JE, Garcia-Pavia P, Ge J, Ho CY, Lakdawala NK, Lewis GD, Maron MS, Martinez MW, Masri A, Maurer MS, Michels M, Mitter SS, Pino Moreno JE, Nagy V, Olivotto I, Owens AT, Poulsen SH, Rader F, Rowin EJ, Ruda M, Schulze PC, Sikand N, Spertus JA, Zhao X, Divanji PH, Heitner SB, Jacoby DL, Kupfer S, Malik FI, Salazar-Mendiguchía J, Wohltman A, Zhuo S, Solomon SD. Effect of Aficamten on Cardiac Structure and Function in Patients With Symptomatic Nonobstructive Hypertrophic Cardiomyopathy. Circulation. 2026 Oct 20; 154(16):1563-1576.
-
Maron MS, Masri A, Bhatia A, Peña-Peña ML, Sherrid MV, Figueiredo EL, Arad M, Choudhury L, Claggett BL, Coats CJ, de Barros Correia E, Costabel JP, Elliott PM, Silva Enciso JE, Ge J, Ho CY, Kulac I, Lewis GD, Martinez MW, Maurer MS, Michels M, Mitter SS, Pino Moreno JE, Olivotto I, Owens AT, Poulsen SH, Rader F, Rowin EJ, Schulze PC, Sepp R, Sikand N, Solomon SD, Spertus JA, Zhao X, Divanji PH, Heitner SB, Jacoby DL, Kupfer S, Malik FI, Salazar-Mendiguchía J, Wohltman A, Zhuo S, Barriales-Villa R. Global Efficacy of Aficamten in Nonobstructive Hypertrophic Cardiomyopathy: Results From ACACIA-HCM. Circulation. 2026 Oct 20; 154(16):1547-1559.
-
Rowin EJ, Maron BJ, Siontis KC, Tower-Rader AF, Massera D, Koethe B, Bilen O, Phelan D, Arnold A, Mohal JS, Varnava AM, Schiavo MA, Ditaranto R, Biagini E, Ahamed H, Hari A, Johar S, Bee-Ngo L, Corrado D, O'Neill J, Semsarian C, Casey SA, Sharkey S, Bonaventura J, Honek J, Krebsova A, Adamova M, McCrystal D, Scherer E, Pillai A, Scalzo M, Jaiswal A, Lax JA, Jurcut R, Kitaok H, Smedsrud MK, Kirshkaln-Leahy A, Francia P, Musumeci B, Hovakimyan T, Kamel O, Yacoub MH, Gunnarsdóttir OB, Gunnarsson GT, Adalsteinsdottir B, Berrios Barcenas EA, Fifer MA, Ommen SR, Sherrid MV, Maron MS. International Experience With Implantable Cardioverter Defibrillators for the Prevention of Sudden Death in High-Risk Patients With Hypertrophic Cardiomyopathy. Circulation. 2026 Oct 06; 154(14):1290-1305.
-
Lewis GD, Garcia-Pavia P, Masri A, Merkely B, Nassif ME, Peña-Peña ML, Barriales-Villa R, Bilen O, Burroughs M, Claggett B, Costabel JP, de Barros Correia E, Dybro AM, Kulac IJ, Lakdawala NK, Mann A, Maron MS, McGinnis S, Nair A, Newlands C, Poulsen SH, Reant P, Schulze PC, Solomon SD, Wang A, Sohn R, Berhane I, Heitner SB, Jacoby DL, Kupfer S, Malik FI, Wohltman A, Fifer MA, Elliott PM. Exercise Performance With Aficamten vs Metoprolol in Obstructive Hypertrophic Cardiomyopathy: The MAPLE-HCM Randomized Clinical Trial. JAMA Cardiol. 2026 Aug 01; 11(8):736-746.
-
Schulz A, Maron MS, Peng LW, Maron BA, Amyar A, Ngo L, Olivotto I, Chan RH, Manning WJ, Rowin EJ, Nezafat R. Clinical Course and Predictors of Heart Failure in Asymptomatic Obstructive Hypertrophic Cardiomyopathy. J Am Heart Assoc. 2026 07 07; 15(13):e048066.
-
Dutta D, Kim Y, Ho CY, Seidman JG, Seidman CE, Craig R, Padrón R. Thick filament molecular interfaces play a critical role in the pathogenesis of hypertrophic cardiomyopathy. Proc Natl Acad Sci U S A. 2026 Jul 07; 123(27):e2529234123.
-
Tower-Rader A, Masri A, Nassif ME, Abraham TP, Barriales-Villa R, Choudhury L, Cooper RM, Elliott PM, Maron MS, Olivotto I, Oreziak A, Owens AT, Solomon SD, Heitner SB, Jacoby DL, Kupfer S, Liu X, Malik FI, Melloni C, Simkins TJ, Wei J, Saberi S. Aficamten in symptomatic obstructive hypertrophic cardiomyopathy: the FOREST-HCM long-term study. Eur Heart J. 2026 Jun 23; 47(24):3120-3131.
-
Kramer CM, Kolm P, DiMarco JP, Desai MY, Ho CY, Kwong RY, Dolman SF, Desvigne-Nickens P, Geller N, Kim DY, Schulz-Menger J, Friedrich MG, Maron MS, Appelbaum E, Link MS, Francis GS, Greenberg B, Jerosch-Herold M, Piechnik S, Mahmod M, Raman B, Jacoby DL, Baldassare LA, White JA, Chiribiri A, Helms AS, Choudhury L, Michels M, Bradlow WM, Salerno M, Heitner SB, Masri A, Prasad SK, Mohiddin SA, Plein S, Madias C, Mahrholdt H, Bucciarelli-Ducci C, Nightingale AK, Weinsaft JW, Kim HW, McCann GP, van Rossum A, Germans T, Williamson EE, Geske JB, Flett AS, Dawson D, Mongeon FP, Olivotto I, Crean AM, Woo A, Owens AT, Anderson L, Sharma S, Biagini E, Newby DE, Andre F, Berry C, Kim B, Larose E, Abraham TP, Hays AG, Sherrid MV, Gelfand EV, Nagueh SF, Rimoldi O, Camici P, Elstein E, Autore C, Watkins H, Weintraub WS, Neubauer S. Predictors of Long-Term Outcomes in Hypertrophic Cardiomyopathy: The NHLBI HCM Registry. JAMA. 2026 Jun 09; 335(22):1959-1969.
-
Sayed A, Rowin EJ, Maron MS, Maron BJ. Demographics and clinical implications of a global bibliographic profile for the hypertrophic cardiomyopathy literature over 66 years (1960-2025). Int J Cardiol. 2026 Sep 15; 459:134571.